Successfully Enterprising BioMed Technologies
Hadasit is recognized around the world for its successful enterprising of the biomedical technologies developed at Hadassah Medical Center. Hadasit boasts a rich portfolio of over 250 patent families, covering a wide variety of novel therapeutics, diagnostics, and medical devices. It has also established dozens of research, license, and option agreements with strategic partners around the world.
To date, Hadasit had spun off over 50 companies, including the publicly-traded Hadasit Bio-Holdings (TASE: HDST) in which Hadasit is a major shareholder. Hadasit holds equity in other publicly-traded companies including Exalenz (TASE: EXEN), OraMed (NASDAQ: ORMP), Immuron (ASX: IMC), and Brainstorm (NASDAQ: BCLI).
We at CardioVia provide the physicians with a minimally invasive access capability to the heart through the pericardium in order to treat the most prevalent Cardiovascular Diseases and arrhythmias without using a needle.
By using cutting edge technologies with the simplest ideas CardioVia will be able to provide physicians with the right access to perform surgeries on the outer surface of the heart like never seen before.
SynCath Neuroscience is a preclinical stage MedTech startup, encapsulating assets of a groundbreaking research program, initiated and led by Prof Ofer Barnea and Dr Omer Doron. Our proprietary technology is based on an ECG-synchronized dynamic ICP-modulation. The technology is realized via a disposable, autonomous ICP modulation probe. The probe is in-dwelling, ECG-synchronized and delivered via an EVD (external ventricular drain) like catheter.
We can no longer ignore the urgency and gravity of the harmful use of antibiotics.
Our technology is the product of 5 years of research, focused on the transmission dynamics of pathogens at the urban and sub-urban spatial resolution scales.
Our product is a data-driven infectious disease diagnosis system that enables the identification of pathogens in real time. The system also supports the recommendation of treatment options for individuals.
Hadasit Bio-Holdings Ltd. (“HBL”) was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) in order to allow public participation in the highly-promising field of biotechnology. HBL serves as a precedent in biotechnology financing – for the first time, public investment is allowed to participate in companies based on IP generated by Israel’s foremost medical research facility, Hadassah Medical Center.
Cell Cure Neurosciences
Cell Cure Neurosciences Ltd., a subsidiary of BioTime, Inc., is a biotechnology company focused on developing cell therapies for retinal and neural degenerative diseases. Cell Cure technology is based on human embryonic stem cells (hESC), which, for the first time in the history of medicine, open the door to industrial-scale manufacture of any cell type in the human body. Cell Cure is using these powerful stem cells to manufacture a particular cell type in the retina called the Retinal Pigment Epithelial (RPE) cell.
Exalenz Bioscience Ltd. develops and commercializes advanced systems that extract vital information for diagnostics from subtle changes in a patient’s exhaled breath based on its BreathID technology platform. These products improve the quality of patient care, enhance clinic and medical center efficiencies, and fuel revenue generation. The company’s proprietary core technology enables medical specialists to identify and manage specific digestive and liver conditions with unprecedented ease, patient comfort, and clinical precision.
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies. Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing type 2 diabetics to begin insulin therapy earlier and without fear of needles. Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.
Enlivex Pharmaceuticals Ltd. is a cell immunotherapy company that is developing an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions which involve over-expression or hyper-expression of cytokines (Cytokine Release Syndrome) such as CAR-T (Chimeric Antigen Receptor) cancer treatment procedures, Graft-versus-Host disease (GvHD) resulting from bone-marrow transplantations, solid organ transplantations, and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis, and other disorders.
KAHR Medical Ltd. (“KAHR”) is an immuno-oncology drug development company whose mission is to develop novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. KAHR’s drug development pipeline is built around the Dual Signaling Proteins (DSP) technology which harnesses the power of the TNF Superfamily (regulators of the immune system) for treatment of disease. KAHR actively operates two drug-development programs, KAHR-101 and KAHR-102, representing proof-of-concept for its two proprietary platforms.
Immuron Ltd. is a publicly-listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally-stable therapeutic as a potential oral targeted therapy for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, arthritis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in their pathogenesis.
Akashi Therapeutics is a clinical stage biopharmaceutical company whose mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Founded by leading patient organizations and biotechnology industry veterans, Akashi is managed by a seasoned team of drug development experts. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a fatal, aggressive muscle-wasting disease to a chronic, manageable condition.
Moebius Medical Ltd. is a clinical stage biotechnology company which is developing a novel and sustainable pain relief treatment for osteoarthritis. The company’s lead product for osteoarthritis of the knee, MM-II, leverages the physical properties of proprietary liposomes to lubricate the joint and reduce friction and wear, thus leading to joint pain reduction.
Medifreeze is the cryopreservation company that operates Hadassah’s stem-cell cord blood bank. At Hadassah’s TaLachaim laboratory, stem cells are produced from a newborn baby’s umbilical cord blood using the Sepax device. Used by the largest banks worldwide, this technology allows for maximal stem cell yield. Processing is performed in in a closed system, with no exposure to human touch or to the air, in order to produce a sterile sample.
PamBio is an innovative biotechnology company developing drug therapy for acute bleeding conditions such as hemorrhagic stroke (intracranial bleeding, ICH). PamBio is an NGT3 VC portfolio company, established in 2014.
Insuline Medical is a publicly-listed Israeli medical device company (INSL.TA). They developed a device that enables patients on intensive insulin therapy to take control of their disease and reach treatment targets in a more effective way. Insuline Medical has been active in developing a new approach to insulin therapy care since 2007, and has developed two medical devices using similar technology. InsuPatch & InsuPad are both designed to improve the current meal-time insulin therapy.
Fidmi Medical is an Israeli start-up company founded in 2014 that is dedicated to developing enhanced feeding devices that offer easy insertion, replacement, and removal. The company operates within Trendlines Medical, a business incubator that is part of the Trendlines Group.
Established in 2015 in Nazareth, Israel, GuideIn is a medical device company specializing in the respiratory field. The company has developed a groundbreaking, non-invasive guided intubation device which enables clear identification of the trachea, as well as fast, accurate and safe intubation even in the most difficult clinical scenarios in which visualization of the trachea is very limited.
Nobio Ltd. is a start-up company developing a proprietary nano-polymer additive that protects against microbial infection which transforms regular implantable and non-implantable devices to biofilm-resistant platforms. These anti-biofilm properties reduce or eliminate device or implant-associated infection, improve clinical outcomes and increase device longevity. The nano-polymer additive is activated only upon contact and does not leak or dissolve into the surrounding environment. This makes it completely safe for patients and, most importantly, preserves the device’s anti-biofilm properties indefinitely.
Cordio Medical Ltd. provides a ground-breaking solution for monitoring CHF patients through free speech into a smartphone app. Cordio Medical technology features a multi-layer voice analysis workflow that indicates changes in a CHF patient’s lung-fluids anatomy. A simple smartphone app at the front end and a sophisticated cluster of proprietary algorithms at the back-end allow remote monitoring of patients anytime and anywhere. Cordio was established in 2013 and entered the Incentive Technology Incubator in 2015 where, with the support of seasoned VC and angel investors, it has been able to accelerate its research and commercialization pathway.
Granalix Ltd. generates innovative formulations of natural compounds that increase their bioavailability and allow them to target organs of interest and, in particular, the brain. The company’s first product – GranaGard – is a submicron self-emulsion formulation of pomegranate seed oil (PSO). PSO contains high concentrations of Punicic Acid (PA), among the strongest natural antioxidants. GranaGard was shown to delay disease onset in a mouse model of genetic prion disease which presents neurodegenerative features reminiscent of Alzheimer’s disease and to reduce disease burden in a mouse model of Multiple Sclerosis.
Swift Duct Medical enables fast and accurate access to the bile duct. Our solution aims to improve the safety of ERCP procedures and reduce post-procedural complications.
BrainWatch Tech is developing a real-time, continuous, automatic pupil reflex monitoring system. Our Solution is intended for assessing the neurological status of unconscious patients in cases of traumatic brain injury, stroke, and brain surgery.
Developing the Next Big Thing
The drugs, medical devices, and cutting-edge technologies developed by Hadasit companies are preventing disease and saving lives. From blockbuster medications like Doxil to the insulin absorption device InsuPad®, Hadasist is taking innovation from the lab to the marketplace.
Doxil is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. Developed by Prof. Yechezkal Barenholz of the Hebrew University and Prof. Alberto Gabizon of Hadassah Medical Center.https://www.doxil.com/
PerioChip is an effective, non-antibiotic adjunct treatment to scaling and root planning to reduce pocket depth in patients with adult periodontitis. PerioChip is a prescription medicine, generally well-tolerated and typically takes just one minute to insert into the periodontal pocket following SRP. Developed by Prof. Michael Friedman and Prof. Doron Steinberg of the Hebrew University and Prof. Aubrey Soskolne of Hadassah Medical Center.http://us.periochip.com/
Travelan is a natural dietary supplement specifically designed to reduce the risk of infection by E. coli (ETEC) as well as Shigella, Salmonella and other bacteria that cause travelers’ diarrhea. The active ingredient in Travelan is hyperimmune bovine colostrum enriched with anti-E. coli antibodies. These antibodies bind to E. coli in the gastrointestinal tract, preventing them from attaching to the intestinal wall and thereby neutralizing their ability to cause diarrhea and its associated symptoms. Developed in collaboration with Prof. Yaron Ilan of Hadassah Medical Center.http://travelan.com/
GranaGard is a submicron self-emulsion formulation of pomegranate seed oil (PSO). PSO contains high concentrations of Punicic Acid (PA), among the strongest natural antioxidants. GranaGard was shown to delay disease onset in a mouse model of genetic prion disease which presents neurodegenerative features reminiscence of Alzheimer’s disease and to reduce disease burden in a mouse model of Multiple Sclerosis. Developed by Prof. Ruth Gabizon of Hadassah Medical Center and Prof. Shlomo Magdassi of the Hebrew University.https://granalix.com/granagard/
InsuPad® enables patients on intensive insulin therapy to take control of their disease and reach treatment targets in more efficient way. By gently warming the skin, it increases blood flow, helping the body absorb insulin better and faster. The result is lower insulin dosage, less hypo, and more freedom. Developed in collaboration with Prof. Itamar Raz of Hadassah Medical Center.http://www.insuline-medical.com/product
The Lubo Collar lets patients breathe to live another day by offering a combined solution for both airway and immobilization needs. It is the only non-invasive solution that can safely open the airway by imitating the jaw thrust maneuver for a long time. The Lubo is the only immobilization device that allows the caregiver to manage the airway easily and frees the neck from the “traditional neck grasp” while performing solid immobilization. Developed by Dr. Omri Lubovsky of Hadassah Medical Center and Dr. Michal Lubovsky of Tel Aviv University.http://www.inovytec.com/lubo/